<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494701</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 396443 - CS1</org_study_id>
    <nct_id>NCT01494701</nct_id>
  </id_info>
  <brief_title>An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)</brief_title>
  <acronym>SMNRx</acronym>
  <official_title>An Open-label, Escalating Dose Study to Assess the Safety, Tolerability and Dose-range Finding of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics
      of a single dose of nusinersen (ISIS 396443) administered intrathecally to participants with
      Spinal Muscular Atrophy (SMA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted and the protocol was registered by Ionis Pharmaceuticals, Inc.

      In August 2016, sponsorship of the trial was transferred to Biogen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2011</start_date>
  <completion_date type="Actual">January 31, 2013</completion_date>
  <primary_completion_date type="Actual">January 31, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants that experience Adverse Events (AEs) and Serious Adverse Events</measure>
    <time_frame>Up to 88 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant neurological examination abnormalities</measure>
    <time_frame>Up to 88 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital sign abnormalities</measure>
    <time_frame>Up to 88 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination abnormalities</measure>
    <time_frame>Up to 88 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant weight abnormalities</measure>
    <time_frame>Up to 88 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory parameters</measure>
    <time_frame>Up to 88 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters</measure>
    <time_frame>Up to 88 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>Up to 88 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who use concomitant medications</measure>
    <time_frame>Up to 88 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>Plasma at 1, 2, 4 and 20 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>Plasma at 1, 2, 4 and 20 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)</measure>
    <time_frame>Plasma at 1, 2, 4 and 20 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible</measure>
    <time_frame>Plasma at 1, 2, 4 and 20 hours after dosing</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (n=6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (n=6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (n=6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (n=10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nusinersen</intervention_name>
    <description>Administered by intrathecal (IT) injection</description>
    <arm_group_label>Cohort 1 (n=6)</arm_group_label>
    <arm_group_label>Cohort 2 (n=6)</arm_group_label>
    <arm_group_label>Cohort 3 (n=6)</arm_group_label>
    <arm_group_label>Cohort 4 (n=10)</arm_group_label>
    <other_name>ISIS 396443</other_name>
    <other_name>BIIB058</other_name>
    <other_name>Spinraza</other_name>
    <other_name>IONIS-SMN Rx</other_name>
    <other_name>ISIS SMNRx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Documented Survival Motor Neuron1 (SMN1) homozygous gene deletion

          -  Clinical signs attributable to Spinal Muscular Atrophy (SMA)

          -  Able to complete all study procedures, measurements and visits and parent/participant
             has adequately supportive psychosocial circumstances, in the opinion of the
             investigator

          -  Estimated life expectancy &gt; 2 years from Screening

          -  Meets age-appropriate institutional criteria for use of anesthesia/sedation, if use is
             planned for study procedure

        Key Exclusion Criteria:

          -  Respiratory insufficiency defined by the need for invasive or non-invasive ventilation
             during a 24 hour period

          -  Presence of a gastric feeding tube

          -  Previous scoliosis surgery or scoliosis surgery planned during the duration of the
             study that would interfere with the lumbar puncture (LP) injection procedure

          -  Hospitalization for surgery or pulmonary event within the last 2 months or planned
             during the study

          -  Presence of an untreated or inadequately treated active infection requiring systemic
             antiviral or antimicrobial therapy

          -  History of brain or spinal cord disease that would interfere with LP procedures or
             cerebrospinal fluid (CSF) circulation

          -  Presence of an implanted shunt for the draining of CSF or an implanted Central Nervous
             System (CNS) catheter

          -  History of bacterial meningitis

          -  Clinically significant abnormalities in hematology or clinical chemistry parameters

          -  Treatment with another investigational drug, biological agent, or device within
             1-month of Screening or 5 half-lives of study agent whichever is longer. Any history
             of gene therapy or cell transplantation

          -  Ongoing medical condition that would interfere with the conduct and assessments of the
             study. Examples are medical disability (e.g. wasting or cachexia, severe anemia, etc.)
             that would interfere with the assessment of safety or would compromised the ability of
             the participant to undergo study procedures

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center - Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.curesma.org</url>
    <description>Cure SMA</description>
  </link>
  <link>
    <url>http://mda.org/disease/spinal-muscular-atrophy</url>
    <description>Muscular Dystrophy Association</description>
  </link>
  <link>
    <url>http://www.rarediseases.org</url>
    <description>National Organization for Rare Diseases</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Muscular Atrophy</keyword>
  <keyword>SMA</keyword>
  <keyword>SMN</keyword>
  <keyword>SMNRx</keyword>
  <keyword>ISIS-SMNRx</keyword>
  <keyword>ISIS-SMN Rx</keyword>
  <keyword>ISIS 396443</keyword>
  <keyword>IONIS-SMNRx</keyword>
  <keyword>IONIS-SMN Rx</keyword>
  <keyword>Spinraza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

